CATALOGO DEI PRODOTTI DELLA RICERCA
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishDNA methylation is a reversible epigenetic phenomenon that can be modified by nutrients such as folate and influenced by the MTHFR677C>T polymorphism in a gene-nutrient interaction manner. In human cancer, global DNA hypomethylation is an almost universal finding.Cancer subjects had lower plasma folate concentrations (P=0.003), higher frequency of MTHFR677TT (P=0.013) and lower PBMCs-DNA methylation than controls (P<0.0001). A DNA methylation threshold of 4.74% categorized cancer patients from controls. Subjects with cancer at follow-up had at enrollment lower DNA methylation than controls (P<0.0001). The association of MTHFR677TT and low plasma folate showed the lowest DNA methylation levels (4.39%). Cancer deaths had a lower DNA methylation compared with other cause deaths (P=0.015) and the survivors had an increased DNA methylation compared to cancer (P=0.004). Low global DNA methylation in PBMCs may be a useful predictive biomarker of cancer.
http://hdl.handle.net/11562/479755| Titolo: | Global DNA hypomethylation in peripheral blood mononuclear cells as a biomarker of cancer risk |
| Autori interni: | GUARINI, Patrizia Udali, Silvia PATTINI, Patrizia MORUZZI, Sara GIRELLI, Domenico PIZZOLO, Francesca MARTINELLI, Nicola OLIVIERI, Oliviero FRISO, Simonetta |
| Data di pubblicazione: | 2013 |
| Rivista: | THE FASEB JOURNAL |
| Abstract: | DNA methylation is a reversible epigenetic phenomenon that can be modified by nutrients such as folate and influenced by the MTHFR677C>T polymorphism in a gene-nutrient interaction manner. In human cancer, global DNA hypomethylation is an almost universal finding.Cancer subjects had lower plasma folate concentrations (P=0.003), higher frequency of MTHFR677TT (P=0.013) and lower PBMCs-DNA methylation than controls (P<0.0001). A DNA methylation threshold of 4.74% categorized cancer patients from controls. Subjects with cancer at follow-up had at enrollment lower DNA methylation than controls (P<0.0001). The association of MTHFR677TT and low plasma folate showed the lowest DNA methylation levels (4.39%). Cancer deaths had a lower DNA methylation compared with other cause deaths (P=0.015) and the survivors had an increased DNA methylation compared to cancer (P=0.004). Low global DNA methylation in PBMCs may be a useful predictive biomarker of cancer. |
| Handle: | http://hdl.handle.net/11562/479755 |
| Appare nelle tipologie: | 01.05 Abstract in rivista |
File in questo prodotto:
Copyright © 2017